Severe ME Day of Understanding and Remembrance: Aug. 8, 2017
Determined to paper the Internet with articles about ME, Jody Smith brings some additional focus to Severe Myalgic Encephalomyelitis Day of Understanding and Remembrance on Aug. 8, 2017 ...
Discuss the article on the Forums.

Assessment of the Fc receptor CD16A of NK cells of CFS patients for potential to mediate ADCC...

Discussion in 'Latest ME/CFS Research' started by Kati, May 28, 2015.

  1. Kati

    Kati Patient in training

    Messages:
    5,464
    Likes:
    19,580
    Assessment of the Fc receptor CD16A of NK cells of CFS patients for potential to mediate ADCC activity (HUM1P.303)

    http://www.jimmunol.org/content/194/1_Supplement/52.28.short

    Abstract:

    Natural killer (NK) cytotoxicity of chronic fatigue syndrome (CFS) patients is decreased, as reported by several laboratories.

    This observation led us to query whether the NK cells also lack antibody-dependent cell-mediated cytotoxicity (ADCC).

    NK cells have the IgG Fc-receptor CD16A that mediates ADCC.

    To assess potential ADCC effectors, we examined the peripheral blood of 11 CFS patients from a Lake Tahoe cohort that met the Fukuda standards for CFS and had low SF36 scores.

    Healthy controls were age- and gender-matched. We stained peripheral blood cells for CD16A with mAb clone 3G8 and for CD3, CD56, and perforin, then assessed the cells by flow cytometry.

    We found that the percentages of NK cells expressing CD16A were slightly lower for CFS patients 86.0+/-11.5% vs. controls 93.0+/-6.6% (P=0.08).

    The median fluorescent indices (MFIs) of CD16A were lower,72% of the values for the CFS patients, 9342+/-3233 vs. control 12929+/-4425, though not statistically significant (P<0.17). Intracellular staining for perforin in the CD16Apos cells was similar for patients and controls.

    Our data indicate that a larger sampling of CFS patients vs. controls is required to determine if the fractions of CD16Apos NK cells and the levels of CD16A on these cells differs.

    These two observations are both in the direction of compromising ADCC activity of patients.

    In addition, a bias in F over V allelic variants of CD16A might add to impairment, since the F allele confers reduced ADCC.

     
  2. Valentijn

    Valentijn Senior Member

    Messages:
    14,281
    Likes:
    45,814
    They're probably referring to rs396991 here, which isn't tested by 23andMe on either the V3 or V4 chips.
     
    leokitten and SOC like this.
  3. Sidereal

    Sidereal Senior Member

    Messages:
    3,097
    Likes:
    17,172
    No "PR replication study" this time then.
     
    Valentijn likes this.

See more popular forum discussions.

Share This Page